Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Discover the importance of using asset allocation to balance risk and return. This strategy can enhance your investment performance.
28,655 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
A high-profile public exchange ended with an apology that reveals valuable money-saving lessons for fans, creators, a...
Viktor has raised $75 million in a Series A to deploy an AI coworker inside Slack and Teams, aiming to automate repet...
A thoughtful tribute to a public figure whose approach to tax policy blends discipline with cooperation. This piece p...
A Gartner forecast signals a seismic shift: 40% of enterprise apps will embed AI agents by 2026. This article breaks ...
BrightSpring’s latest earnings call shed light on growth trends, margin discipline, and a cautious yet hopeful outloo...
Alphabet reports results after the bell, but the line that matters most might be capex. This guide shows how data-cen...
Retirees aiming for $10,000 a month at 65 face a tight budget once taxes, Medicare premiums, and rising costs are app...
A major hedge fund slashed its stake in Structure Therapeutics, prompting questions about the future path for GPCR-fo...
As incoming Fed Chair Warsh signals a renewed focus on inflation, traders weigh the odds of higher-for-longer policy ...
A Wall Street Journal probe alleges polymarket used staged bets to fuel viral growth, prompting questions about trans...
A federal court hearing in New York is set to scrutinize how the government plans to deliver refunds from the $166 bi...